Review of the fibrinolytic system : comparison of different antifibrinolytics used during cardiopulmonary bypass
Antifibrinolytic agents are often used in different clinical situations, especially in cardiac surgery. During several years, aprotinin was the drug of choice because more than antifibrinolytic properties, aprotinin offers a direct effect on kallikrein and inflammatory pathways. In 2008, The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) initiated a discussion about real risks associated with aprotinin administration. Tranexamic acid and epsilon-aminocaproic acid appear to be interesting alternatives in our daily practice. The exact mechanism of action, the pharmacokinetic parameters, the efficacy, and the safety profile need to be clarified for lysine analogs. In this review, the different antifibrinolytics will be described with a special interest into the route of work, and recent patents. Current studies about the pharmacokinetic and the pharmacodynamic profile will be described, and finally the benefit-to-risk balance in patients undergoing cardiac surgery with cardiopulmonary bypass will be discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Recent patents on cardiovascular drug discovery - 7(2012), 3 vom: 04. Dez., Seite 175-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Van Aelbrouck, Caroline [VerfasserIn] |
|---|
| Themen: |
Antifibrinolytic Agents |
|---|
| Anmerkungen: |
Date Completed 04.09.2013 Date Revised 12.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM221557415 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM221557415 | ||
| 003 | DE-627 | ||
| 005 | 20231224052142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0738.xml |
| 035 | |a (DE-627)NLM221557415 | ||
| 035 | |a (NLM)23035827 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Van Aelbrouck, Caroline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review of the fibrinolytic system |b comparison of different antifibrinolytics used during cardiopulmonary bypass |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2013 | ||
| 500 | |a Date Revised 12.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antifibrinolytic agents are often used in different clinical situations, especially in cardiac surgery. During several years, aprotinin was the drug of choice because more than antifibrinolytic properties, aprotinin offers a direct effect on kallikrein and inflammatory pathways. In 2008, The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) initiated a discussion about real risks associated with aprotinin administration. Tranexamic acid and epsilon-aminocaproic acid appear to be interesting alternatives in our daily practice. The exact mechanism of action, the pharmacokinetic parameters, the efficacy, and the safety profile need to be clarified for lysine analogs. In this review, the different antifibrinolytics will be described with a special interest into the route of work, and recent patents. Current studies about the pharmacokinetic and the pharmacodynamic profile will be described, and finally the benefit-to-risk balance in patients undergoing cardiac surgery with cardiopulmonary bypass will be discussed | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antifibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Englberger, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Faraoni, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recent patents on cardiovascular drug discovery |d 2006 |g 7(2012), 3 vom: 04. Dez., Seite 175-9 |w (DE-627)NLM167487183 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2012 |g number:3 |g day:04 |g month:12 |g pages:175-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2012 |e 3 |b 04 |c 12 |h 175-9 | ||